Category Archives: Strategy
By Casey McDonald | Published: November 20, 2014
CytRx announced on Tuesday that FDA gave notice of a partial clinical hold for trials for its oncology candidate aldoxorubicin. The hold results from a reported death of a late-stage cancer patient “who did not qualify to participate in any of the ongoing aldoxorubicin clinical trials, but had received aldoxorubicin under the Company’s expanded access […]
By Tom Norton | Published: November 19, 2014
While flipping through my emails recently, I froze before an image that appeared on my screen. An old Rx colleague had sent me a graph, mapping out the 2014 U.S. sales achieved by Gilead’s Hep C drug, Sovaldi. It was stunning. Take a look:
By Pharm Exec | Published: November 19, 2014
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.
By Casey McDonald | Published: November 12, 2014
Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the R&D industry’s global trade group based in Geneva.
By Guest Blogger | Published: November 4, 2014
By Wayne Kubick, Applied Clinical Trials. We hear it all the time these days: research processes have to undergo transformative changes in order for research organizations to thrive—or even survive. Controlled clinical trials take too long and cost too much. Regulatory review is blocking innovation. Research data must be shared transparently, drug manufacturers need to […]